TVCMALL brings one-stop wholesale solution to MWC 2023
10.3.2023 15:57:00 EET | Business Wire | Press release
Recently, the 2023 Mobile World Congress (MWC) held in Barcelona turned out to be a big success. More than 88,000 attendees and 2400+ exhibitors participated in this event, including many cell phone accessories suppliers & wholesalers. As Europe's leading one-stop shop for mobile accessories and wholesale/integrated supply chain service platform, TVCMALL participated in this digital/mobile feast. TVCMALL, based in Shenzhen China, the world's electronic center, provides the esteemed customer B2B solution on mobile accessories for wholesale, sourcing, and customization. Various classic mobile cases with leather finishing, chargers with multifunctions, and Amorus portable Karaoke speaker brought by TVCMALL were highly praised by our attendees.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230307005650/en/
TVCMALL brings one-stop wholesale solution to MWC 2023 (Photo: Business Wire)
MWC is one of the world's most important telecommunications & technology shows. During the past 4 days, the aspects such as the latest trend in mobile technologies, including Intelligent equipment, 5G network, AI, and digitalization, have been introduced and shared with the world.
During the show, TVCMALL met a lot of old customers and new friends. Many of them are as follows:
- Top online mobile phone accessories retailers & distributors
- B2C platform sellers, Dropshippers
- Offline chain stores, Supermarket sellers, Telecom companies
- Gift-Customize customers (especially for government, corporate & schools and other agents)
- OEM & ODM & OBM customers
- Retail shops & Mobile phone repair shops
Many customers have cooperated with TVCMALL for over ten years since its establishment in 2008, and they have grown and developed rapidly with TVCMALL. They expressed their high recognition and gratitude to TVCMALL for providing one-stop wholesale, sourcing, customized services, and other supply chain services.
Why they choose TVCMALL as an indispensable and important long-term partner? Because TVCMALL provides complete product catalog, with more than 600,000 SKU online, and every week 6,000 new products updated. Its wholesale process, marketing support, and customer service are efficient. TVCMALL has good intention of growing together with their customers.
TVCMALL's comprehensive procurement cost is relatively low, the service consistency and stability are very strong. That’s why many customers prefer one-stop service providers like TVCMALL.
During the MWC, TVCMALL has established a bridge of contact with some excellent product suppliers and e-commerce service providers (of mobile, 3C electronic devices and accessories).
In the foreseeable future, with continuously TVCMALL brand and platform upgrading, TVCMALL will strengthen its mission, "To help entrepreneurs actualize their dreams of launching and sustaining a successful retail business", and will stick to its business operation philosophy "Together we thrive". In terms of specific strategies, TVCMALL will adhere to the following 4 directions:
- Platform Branding — Operate the TVCMALL platform as a future century-old brand
- Productization of the services — all the services of TVCMALL with the idea of Productization.
- Product Deep ploughing — Thrive to be the best.
- Localization of TVCMALL service — Go global and localization: Initiate local marketing and service team, in-depth understanding & efficient service.
TVCMALL will see you again in Barcelona 2024!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005650/en/
Contact information
Shenzhen Zhenzhi Technology Co.,Ltd.
Yelly Huang
global@tvcmall.com
https://www.tvcmall.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom